Axsome Therapeutics, Inc.

NASDAQ:AXSM

Biotechnology

Healthcare
$134.00 +0.10%

+$0.25 today

Market cap
$7.05B
Beta
0.60
P/E (TTM)
-68.6
EPS (TTM)
-$3.68
52W Low $96.09High $257.93

Volume 0.74M

Average 0.72M

AXSM EBITDA Margin

EBITDA as a percentage of revenue.

Axsome Therapeutics, Inc.NASDAQ: AXSM

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to -21.4%

EBITDA Margin was -21.4% in Q2 FY2026, up 7.0 pp from a year earlier. On a trailing-twelve-month basis it was -22.7%, up 23.5 pp year over year. Over 3 fiscal years it widened by 324.2 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 16 analysts of -11.9% for the fiscal year ending Dec 2026, up from -26.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-21.4%+10.5 pp QoQ
Last fiscal yearDec 2025
-26.3%+44.4 pp YoY
LTMJun 2026
-22.7%+23.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.0 pp+14.0 pp+7.1 pp
1 year+44.4 pp+14.5 pp-29.9 pp
3 years+324.2 pp+64.1 pp-260.1 pp
5 years+74.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-26.3%
Year-over-year change
+44.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How AXSM compares with its peers on the latest reported figures

  • AXSM's LTM Jun 2026 EBITDA Margin of -22.7% is the 4th highest of the 7 companies compared; the peer median is -296.3%.
  • Its year-over-year change of +23.5 pp is the highest of 4, against a peer median of +0.3 pp.
  • Over three fiscal years its change of +324.2 pp compares with a peer median of -25.5 pp.
AXSM Competitors Peer median
EBITDA Margin for AXSM and competitors
Company Period LTM level YoY 3-year change
NBIXNeurocrine Biosciences, Inc.LTM Sep 202625.7% +0.3 pp+7.4 pp
JAZZJazz Pharmaceuticals plcLTM Sep 202621.0% +14.8 pp-34.0 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-1.9% -26.9 pp-17.1 pp
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-22.7% +23.5 pp+324.2 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-590.7% ——
XENEXenon Pharmaceuticals Inc.FY2025-4564.7% —-3210.7 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-13823.7% ——
PRAXPraxis Precision Medicines, Inc.FY2025— ——
DFTXDefinium Therapeutics, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding AXSM) -296.3%+0.3 pp-25.5 pp

Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue050.04M270.6M385.69M638.5M
Cost of Revenue05.2M26.07M33.3M47.48M
Gross Profit044.84M244.54M352.39M591.02M
Gross Margin—89.6%90.4%91.4%92.6%
Research & Development58.06M57.95M97.94M187.08M183.28M
Selling, General & Admin66.65M159.25M323.12M411.36M570.6M
Operating Expenses124.71M224.64M476.36M632.95M760.25M
Depreciation & Amortization76K4.4M6.83M7.96M9.06M
EBITDA(124.63M)(175.4M)(224.99M)(272.6M)(168.08M)
EBITDA Margin—-350.5%-83.1%-70.7%-26.3%
Operating Income(124.71M)(179.8M)(231.83M)(280.56M)(169.24M)
Operating Margin—-359.3%-85.7%-72.7%-26.5%
Interest Income00009.37M
Interest Expense5.7M7.34M6.45M6.57M6.56M
Other Income / Expenses(5.7M)(7.34M)(6.45M)(6.57M)(14.47M)
Income Before Tax(130.4M)(187.13M)(238.28M)(287.13M)(183.7M)
Pre-Tax Margin—-374.0%-88.1%-74.4%-28.8%
Income Tax Expense00960K85K(530K)
Net Income(130.4M)(187.13M)(239.24M)(287.22M)(183.17M)
Net Margin—-374.0%-88.4%-74.5%-28.7%
EPS (Basic)(3.47)(4.60)(5.27)(5.99)(3.68)
EPS (Diluted)(3.47)(4.60)(5.27)(5.99)(3.68)
Weighted Avg Shares37.62M40.66M45.43M47.91M49.75M
Weighted Avg Shares (Diluted)37.62M40.66M45.43M47.91M49.75M

Axsome Therapeutics, Inc.

NASDAQ:AXSM

Intrinsic Alpha fair value

Locked

Current Price

$134.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.